{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:03:59Z","timestamp":1791237839921,"version":"4.1.0"},"reference-count":235,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023479","name":"CRIS Cancer Foundation","doi-asserted-by":"publisher","award":["PR_EX_22-36"],"award-info":[{"award-number":["PR_EX_22-36"]}],"id":[{"id":"10.13039\/501100023479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","award":["488\/C\/2019"],"award-info":[{"award-number":["488\/C\/2019"]}],"id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014599","name":"Mark Foundation For Cancer Research","doi-asserted-by":"publisher","award":["ASPIRE Award"],"award-info":[{"award-number":["ASPIRE Award"]}],"id":[{"id":"10.13039\/100014599","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018779","name":"Fundaci\u00f3n Fero","doi-asserted-by":"publisher","award":["BBASELGAFERO2022-01"],"award-info":[{"award-number":["BBASELGAFERO2022-01"]}],"id":[{"id":"10.13039\/501100018779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","award":["PID:2020-112892RB"],"award-info":[{"award-number":["PID:2020-112892RB"]}],"id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI21\/01547[CEDA]"],"award-info":[{"award-number":["PI21\/01547[CEDA]"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010434","name":"'la Caixa\u2019 Foundation","doi-asserted-by":"publisher","award":["LCF\/PR\/HR21\/00083"],"award-info":[{"award-number":["LCF\/PR\/HR21\/00083"]}],"id":[{"id":"10.13039\/100010434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["CLJUN20011EGUR"],"award-info":[{"award-number":["CLJUN20011EGUR"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["LABAE211756FERN"],"award-info":[{"award-number":["LABAE211756FERN"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,9,13]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Almost every successful anticancer treatment has been preceded by preclinical scientific breakthroughs that encouraged clinical development. However, therapeutic strategies showing promising preclinical results often fail to confirm activity in clinical trials, particularly in immunotherapy. There are well-known inherent interspecies differences between human and rodent immunobiology. Moreover, human cancers progressively develop in nature over long periods, while preclinical models are deployed under controlled laboratory conditions. This translates into a suboptimal recapitulation of key features of human cancer, such as the marked interindividual differences, intercellular heterogeneity, and the immunoediting effects of chronic immunosurveillance. This review summarizes the current evidence of preclinical experimental models and research tools for cancer immunotherapy applications, with a focus on the incorporation of human sample-based methodologies, both ex vivo and in vivo using humanized mouse models. Methods to exploit highly valuable human specimens in preclinical research are called to bridge the gap between discovery observations in conventional mouse models and efficacy\/safety tests in clinical trials. Novel immunotherapy agents and their combinations can be prioritized based on their effects on in vitro patient-derived tumor culture modalities or on as-perfect-as-feasible humanized mouse models bearing human tumor and immune cells. The ultimate goal is to reliably test immunotherapy interventions and reduce eventual clinical failures by means of preclinically prioritizing the best approaches.<\/jats:p>","DOI":"10.1136\/jitc-2024-011279","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T10:40:56Z","timestamp":1761734456000},"page":"e011279","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":12,"title":["Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1581-3728","authenticated-orcid":false,"given":"I\u00f1aki","family":"Eguren-Santamaria","sequence":"first","affiliation":[{"name":"Immunology and Immunotherapy, Clinica Universidad de Navarra Centro de Investigacion Medica Aplicada, Pamplona, Navarre, Spain"},{"name":"Department of Oncology, Clinica Universidad de Navarra Cancer Center, Pamplona, Navarre, Spain"},{"name":"IdiSNA, Pamplona, Navarre, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-348X","authenticated-orcid":false,"suffix":"PhD","given":"Ignacio","family":"Melero","sequence":"additional","affiliation":[{"name":"Immunology and Immunotherapy, Clinica Universidad de Navarra Centro de Investigacion Medica Aplicada, Pamplona, Navarre, Spain"},{"name":"IdiSNA, Pamplona, Navarre, Spain"},{"name":"CIBERONC, Madrid, Community of Madrid, Spain"},{"name":"Immune Regulation and Immune Interactions Group, Centre for Immuno-Oncology, University of Oxford Nuffield Department of Medicine, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Immunology and Immunotherapy, Clinica Universidad de Navarra Centro de Investigacion Medica Aplicada, Pamplona, Navarre, Spain"},{"name":"IdiSNA, Pamplona, Navarre, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Ortego","sequence":"additional","affiliation":[{"name":"Department of Oncology, Clinica Universidad de Navarra Cancer Center, Pamplona, Navarre, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Armero","sequence":"additional","affiliation":[{"name":"Immune Regulation and Immune Interactions Group, Centre for Immuno-Oncology, University of Oxford Nuffield Department of Medicine, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Galvez-Cancino","sequence":"additional","affiliation":[{"name":"Immune Regulation and Immune Interactions Group, Centre for Immuno-Oncology, University of Oxford Nuffield Department of Medicine, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5744-3115","authenticated-orcid":false,"given":"Alvaro","family":"L\u00f3pez-Janeiro","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinica Universidad de Navarra Cancer Center, Pamplona, Navarre, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos E","family":"De Andrea","sequence":"additional","affiliation":[{"name":"IdiSNA, Pamplona, Navarre, Spain"},{"name":"CIBERONC, Madrid, Community of Madrid, Spain"},{"name":"Department of Pathology, Clinica Universidad de Navarra Cancer Center, Pamplona, Navarre, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7295-6074","authenticated-orcid":false,"given":"Miguel F","family":"Sanmamed","sequence":"additional","affiliation":[{"name":"Immunology and Immunotherapy, Clinica Universidad de Navarra Centro de Investigacion Medica Aplicada, Pamplona, Navarre, Spain"},{"name":"Department of Oncology, Clinica Universidad de Navarra Cancer Center, Pamplona, Navarre, Spain"},{"name":"IdiSNA, Pamplona, Navarre, Spain"},{"name":"CIBERONC, Madrid, Community of Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2026041300250642000_13.10.e011279.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734"},{"key":"2026041300250642000_13.10.e011279.2","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxh194"},{"key":"2026041300250642000_13.10.e011279.3","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620"},{"key":"2026041300250642000_13.10.e011279.4","doi-asserted-by":"publisher","DOI":"10.1038\/nature25492"},{"key":"2026041300250642000_13.10.e011279.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.08.018"},{"key":"2026041300250642000_13.10.e011279.6","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-2-3"},{"key":"2026041300250642000_13.10.e011279.7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30274-8"},{"key":"2026041300250642000_13.10.e011279.8","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-14471-1","article-title":"Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy","volume":"11","author":"Sharma","year":"2020","journal-title":"Nat Commun"},{"key":"2026041300250642000_13.10.e011279.9","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1200\/JCO.23.00172","article-title":"Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results","volume":"41","author":"Diab","year":"2023","journal-title":"J Clin Oncol"},{"key":"2026041300250642000_13.10.e011279.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1355"},{"key":"2026041300250642000_13.10.e011279.11","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1559"},{"key":"2026041300250642000_13.10.e011279.12","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0222"},{"key":"2026041300250642000_13.10.e011279.13","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41586-019-1330-0","article-title":"Immune evasion before tumour invasion in early lung squamous carcinogenesis","volume":"571","author":"Mascaux","year":"2019","journal-title":"Nature New Biol"},{"key":"2026041300250642000_13.10.e011279.14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.immuni.2016.03.004","article-title":"Cancer Immunosurveillance Caught in the Act","volume":"44","author":"Berraondo","year":"2016","journal-title":"Immunity"},{"key":"2026041300250642000_13.10.e011279.15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.5.2731"},{"key":"2026041300250642000_13.10.e011279.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI82416"},{"key":"2026041300250642000_13.10.e011279.17","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4051"},{"key":"2026041300250642000_13.10.e011279.18","doi-asserted-by":"publisher","DOI":"10.1126\/science.abl5447"},{"key":"2026041300250642000_13.10.e011279.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02210-6"},{"key":"2026041300250642000_13.10.e011279.20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"Oncoimmunology"},{"key":"2026041300250642000_13.10.e011279.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-03301-0","article-title":"Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer","volume":"9","author":"Bobisse","year":"2018","journal-title":"Nat Commun"},{"key":"2026041300250642000_13.10.e011279.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0040-8"},{"key":"2026041300250642000_13.10.e011279.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.03.001"},{"key":"2026041300250642000_13.10.e011279.24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad1253"},{"key":"2026041300250642000_13.10.e011279.25","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-022-00174-y","article-title":"Organoids","volume":"2","author":"Zhao","year":"2022","journal-title":"Nat Rev Methods Primers"},{"key":"2026041300250642000_13.10.e011279.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.009"},{"key":"2026041300250642000_13.10.e011279.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8"},{"key":"2026041300250642000_13.10.e011279.28","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003213","article-title":"Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids","volume":"9","author":"Meng","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.29","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-024-03749-8","article-title":"Identification and validation of tumor-specific T cell receptors from tumor infiltrating lymphocytes using tumor organoid co-cultures","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"2026041300250642000_13.10.e011279.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01397-w"},{"key":"2026041300250642000_13.10.e011279.31","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100928","article-title":"3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids","volume":"38","author":"Schnalzger","year":"2019","journal-title":"EMBO J"},{"key":"2026041300250642000_13.10.e011279.32","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-08143-8"},{"key":"2026041300250642000_13.10.e011279.33","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.006"},{"key":"2026041300250642000_13.10.e011279.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.08.016"},{"key":"2026041300250642000_13.10.e011279.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107588"},{"key":"2026041300250642000_13.10.e011279.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0584-2"},{"key":"2026041300250642000_13.10.e011279.37","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2020.100161","article-title":"An Automated Organoid Platform with Inter-organoid Homogeneity and Inter-patient Heterogeneity","volume":"1","author":"Jiang","year":"2020","journal-title":"Cell Rep Med"},{"key":"2026041300250642000_13.10.e011279.38","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0833"},{"key":"2026041300250642000_13.10.e011279.39","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0689"},{"key":"2026041300250642000_13.10.e011279.40","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-01013-x","article-title":"3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells","volume":"7","author":"Parlato","year":"2017","journal-title":"Sci Rep"},{"key":"2026041300250642000_13.10.e011279.41","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201900289","article-title":"Microfluidic Model for Evaluation of Immune Checkpoint Inhibitors in Human Tumors","volume":"8","author":"Beckwith","year":"2019","journal-title":"Adv Healthc Mater"},{"key":"2026041300250642000_13.10.e011279.42","doi-asserted-by":"crossref","first-page":"111508","DOI":"10.1016\/j.yexcr.2019.111508","article-title":"In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients","volume":"383","author":"Al-Samadi","year":"2019","journal-title":"Exp Cell Res"},{"key":"2026041300250642000_13.10.e011279.43","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41587-024-02301-4","article-title":"Patient-derived mini-colons enable long-term modeling of tumor-microenvironment complexity","volume":"43","author":"Lorenzo-Mart\u00edn","year":"2025","journal-title":"Nat Biotechnol"},{"key":"2026041300250642000_13.10.e011279.44","doi-asserted-by":"crossref","unstructured":"Virumbrales-Mu\u00f1oz M , Ayuso JM , Loken JR , et al . Microphysiological model of renal cell carcinoma to inform anti-angiogenic therapy. Biomaterials 2022;283. doi:10.1016\/j.biomaterials.2022.121454","DOI":"10.1016\/j.biomaterials.2022.121454"},{"key":"2026041300250642000_13.10.e011279.45","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202302903","article-title":"Microfluidic-Based Reconstitution of Functional Lymphatic Microvasculature: Elucidating the Role of Lymphatics in Health and Disease","volume":"11","author":"Serrano","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"2026041300250642000_13.10.e011279.46","doi-asserted-by":"crossref","unstructured":"Goyal G , Prabhala P , Mahajan G , et al . Ectopic Lymphoid Follicle Formation and Human Seasonal Influenza Vaccination Responses Recapitulated in an Organ\u2010on\u2010a\u2010Chip. Adv Sci (Weinh) 2022;9. doi:10.1002\/advs.202103241","DOI":"10.1002\/advs.202270090"},{"key":"2026041300250642000_13.10.e011279.47","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx727","article-title":"Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy","volume":"28","author":"S\u00e1nchez-Paulete","year":"2017","journal-title":"Ann Oncol"},{"key":"2026041300250642000_13.10.e011279.48","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13101657","article-title":"Multi-Organs-on-Chips for Testing Small-Molecule Drugs: Challenges and Perspectives","volume":"13","author":"Cecen","year":"2021","journal-title":"Pharmaceutics"},{"key":"2026041300250642000_13.10.e011279.49","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-33462-3","article-title":"Simultaneous evaluation of anti-EGFR-induced tumour and adverse skin effects in a microfluidic human 3D co-culture model","volume":"8","author":"H\u00fcbner","year":"2018","journal-title":"Sci Rep"},{"key":"2026041300250642000_13.10.e011279.50","doi-asserted-by":"crossref","unstructured":"McAleer CW , Long CJ , Elbrecht D , et al . Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics. Sci Transl Med 2019;11. doi:10.1126\/scitranslmed.aav1386","DOI":"10.1126\/scitranslmed.aav1386"},{"key":"2026041300250642000_13.10.e011279.51","doi-asserted-by":"publisher","DOI":"10.1039\/D0LC00424C"},{"key":"2026041300250642000_13.10.e011279.52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41586-023-05704-6","article-title":"Targeting TBK1 to overcome resistance to cancer immunotherapy","volume":"615","author":"Sun","year":"2023","journal-title":"Nature New Biol"},{"key":"2026041300250642000_13.10.e011279.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01398-3"},{"key":"2026041300250642000_13.10.e011279.54","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.11.021"},{"key":"2026041300250642000_13.10.e011279.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2022.04.006"},{"key":"2026041300250642000_13.10.e011279.56","doi-asserted-by":"crossref","first-page":"102282","DOI":"10.1016\/j.xpro.2023.102282","article-title":"Protocol for ex vivo culture of patient-derived tumor fragments","volume":"4","author":"Roelofsen","year":"2023","journal-title":"STAR Protocols"},{"key":"2026041300250642000_13.10.e011279.57","doi-asserted-by":"crossref","unstructured":"Shekarian T , Zinner CP , Bartoszek EM , et al . Immunotherapy of glioblastoma explants induces interferon-\u03b3 responses and spatial immune cell rearrangements in tumor center, but not periphery. Sci Adv 2022;8. doi:10.1126\/sciadv.abn9440","DOI":"10.1126\/sciadv.abn9440"},{"key":"2026041300250642000_13.10.e011279.58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.02.013"},{"key":"2026041300250642000_13.10.e011279.59","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s43018-023-00712-x","article-title":"The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2","volume":"5","author":"Chaib","year":"2024","journal-title":"Nat Cancer"},{"key":"2026041300250642000_13.10.e011279.60","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/path.1700330219","article-title":"A transplantable melanoma of the mouse","volume":"33","author":"Harding","year":"1930","journal-title":"J Pathol"},{"key":"2026041300250642000_13.10.e011279.61","first-page":"438","article-title":"Studies in a tumor spectrum. VIII. The effect of mitomycin C on the growth of a variety of mouse, rat, and hamster tumors","volume":"19","author":"SUGIURA","year":"1959","journal-title":"Cancer Res"},{"key":"2026041300250642000_13.10.e011279.62","unstructured":"Corbett TH , Griswold DP , Roberts BJ , et al . Tumor Induction Relationships in Development of Transplantable Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen Structure1. Cancer Res (1975) 1975. Available: https:\/\/aacrjournals.org\/cancerres\/article\/35\/9\/2434\/480826\/Tumor-Induction-Relationships-in-Development-of"},{"key":"2026041300250642000_13.10.e011279.63","unstructured":"Foley EJ . Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. 2024. Available: http:\/\/aacrjournals.org\/cancerres\/article-pdf\/13\/12\/835\/2344645\/cr0130120835.pdf"},{"key":"2026041300250642000_13.10.e011279.64","doi-asserted-by":"publisher","DOI":"10.1038\/35074122"},{"key":"2026041300250642000_13.10.e011279.65","doi-asserted-by":"publisher","DOI":"10.1038\/ni1213"},{"key":"2026041300250642000_13.10.e011279.66","doi-asserted-by":"publisher","DOI":"10.1038\/nature06309"},{"key":"2026041300250642000_13.10.e011279.67","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/315115a0","article-title":"Heritable formation of pancreatic \u03b2-cell tumours in transgenic mice expressing recombinant insulin\/simian virus 40 oncogenes","volume":"315","author":"Hanahan","year":"1985","journal-title":"Nature New Biol"},{"key":"2026041300250642000_13.10.e011279.68","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5335.120"},{"key":"2026041300250642000_13.10.e011279.69","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/26.6.1427"},{"key":"2026041300250642000_13.10.e011279.70","doi-asserted-by":"publisher","DOI":"10.1038\/15073"},{"key":"2026041300250642000_13.10.e011279.71","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3646"},{"key":"2026041300250642000_13.10.e011279.72","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0613-1"},{"key":"2026041300250642000_13.10.e011279.73","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0283"},{"key":"2026041300250642000_13.10.e011279.74","doi-asserted-by":"publisher","DOI":"10.1016\/J.IMMUNI.2016.07.011"},{"key":"2026041300250642000_13.10.e011279.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06797-9"},{"key":"2026041300250642000_13.10.e011279.76","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.08.015"},{"key":"2026041300250642000_13.10.e011279.77","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0074"},{"key":"2026041300250642000_13.10.e011279.78","doi-asserted-by":"crossref","first-page":"101009","DOI":"10.1016\/j.xcrm.2023.101009","article-title":"Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma","volume":"4","author":"Ochoa","year":"2023","journal-title":"Cell Reports Medicine"},{"key":"2026041300250642000_13.10.e011279.79","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01868-2"},{"key":"2026041300250642000_13.10.e011279.80","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1613601113"},{"key":"2026041300250642000_13.10.e011279.81","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01499-4"},{"key":"2026041300250642000_13.10.e011279.82","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07135-3"},{"key":"2026041300250642000_13.10.e011279.83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.011"},{"key":"2026041300250642000_13.10.e011279.84","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/nature03954","article-title":"Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance","volume":"437","author":"Willimsky","year":"2005","journal-title":"Nature New Biol"},{"key":"2026041300250642000_13.10.e011279.85","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(88)91043-4"},{"key":"2026041300250642000_13.10.e011279.86","doi-asserted-by":"publisher","DOI":"10.1038\/nm0795-649"},{"key":"2026041300250642000_13.10.e011279.87","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3259"},{"key":"2026041300250642000_13.10.e011279.88","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature New Biol"},{"key":"2026041300250642000_13.10.e011279.89","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.18.9730"},{"key":"2026041300250642000_13.10.e011279.90","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/336073a0","article-title":"Positive and negative selection of an antigen receptor on T cells in transgenic mice","volume":"336","author":"Sha","year":"1988","journal-title":"Nature New Biol"},{"key":"2026041300250642000_13.10.e011279.91","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(94)90169-4"},{"key":"2026041300250642000_13.10.e011279.92","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030590"},{"key":"2026041300250642000_13.10.e011279.93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-023069"},{"key":"2026041300250642000_13.10.e011279.94","doi-asserted-by":"crossref","unstructured":"Moore MJ , Zhong M , Hansen J , et al . Humanization of T cell\u2013mediated immunity in mice. Sci Immunol 2021;6. doi:10.1126\/sciimmunol.abj4026","DOI":"10.1126\/sciimmunol.abj4026"},{"key":"2026041300250642000_13.10.e011279.95","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0040"},{"key":"2026041300250642000_13.10.e011279.96","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-023-00809-z"},{"key":"2026041300250642000_13.10.e011279.97","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1158\/1078-0432.CCR-23-0006","article-title":"Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas","volume":"29","author":"Stinson","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026041300250642000_13.10.e011279.98","doi-asserted-by":"crossref","unstructured":"Stinson JA , Barbosa MMP , Sheen A , et al . Tumor-localized interleukin-2 and interleukin-12 combine with radiation therapy to safely potentiate regression of advanced malignant melanoma in pet dogs. Cancer Biology [Preprint]. doi:10.1101\/2024.02.12.579965 Available: https:\/\/www.biorxiv.org\/content\/10.1101\/2024.02.12.579965v1","DOI":"10.1101\/2024.02.12.579965"},{"key":"2026041300250642000_13.10.e011279.99","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cvsm.2023.12.002","article-title":"Cancer Immunotherapy","volume":"54","author":"Bergman","year":"2024","journal-title":"Vet Clin North Am Small Anim Pract"},{"key":"2026041300250642000_13.10.e011279.100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.5493\/wjem.v7.i2.42","article-title":"Recent clinical trials of cancer immunogene therapy in companion animals","volume":"7","author":"Finocchiaro","year":"2017","journal-title":"WJEM"},{"key":"2026041300250642000_13.10.e011279.101","doi-asserted-by":"crossref","first-page":"6251","DOI":"10.4049\/jimmunol.171.11.6251","article-title":"Activity and Safety of CTLA-4 Blockade Combined with Vaccines in Cynomolgus Macaques","volume":"171","author":"Keler","year":"2003","journal-title":"The Journal of Immunology"},{"key":"2026041300250642000_13.10.e011279.102","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0040"},{"key":"2026041300250642000_13.10.e011279.103","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1533209100"},{"key":"2026041300250642000_13.10.e011279.104","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842"},{"key":"2026041300250642000_13.10.e011279.105","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2298"},{"key":"2026041300250642000_13.10.e011279.106","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20182359"},{"key":"2026041300250642000_13.10.e011279.107","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1156"},{"key":"2026041300250642000_13.10.e011279.108","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1203954109"},{"key":"2026041300250642000_13.10.e011279.109","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1158\/0008-5472.CAN-23-2701","article-title":"ATG-101 Is a Tetravalent PD-L1\u00d74-1BB Bispecific Antibody That Stimulates Antitumor Immunity through PD-L1 Blockade and PD-L1-Directed 4-1BB Activation","volume":"84","author":"Yuwen","year":"2024","journal-title":"Cancer Res"},{"key":"2026041300250642000_13.10.e011279.110","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.02.010"},{"key":"2026041300250642000_13.10.e011279.111","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2825"},{"key":"2026041300250642000_13.10.e011279.112","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830221115"},{"key":"2026041300250642000_13.10.e011279.113","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw041"},{"key":"2026041300250642000_13.10.e011279.114","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg4498","article-title":"Rejection of benign melanocytic nevi by nevus-resident CD4+ T cells","volume":"7","author":"Schiferle","year":"2021","journal-title":"Sci Adv"},{"key":"2026041300250642000_13.10.e011279.115","doi-asserted-by":"crossref","first-page":"898","DOI":"10.4049\/jimmunol.174.2.898","article-title":"Human CD4+ Effector Memory T Cells Persisting in the Microenvironment of Lung Cancer Xenografts Are Activated by Local Delivery of IL-12 to Proliferate, Produce IFN-\u03b3, and Eradicate Tumor Cells","volume":"174","author":"Broderick","year":"2005","journal-title":"The Journal of Immunology"},{"key":"2026041300250642000_13.10.e011279.116","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.4049\/jimmunol.180.10.7009","article-title":"Long-Term Engraftment and Expansion of Tumor-Derived Memory T Cells Following the Implantation of Non-Disrupted Pieces of Human Lung Tumor into NOD-scid IL2R\u03b3null Mice","volume":"180","author":"Simpson-Abelson","year":"2008","journal-title":"The Journal of Immunology"},{"key":"2026041300250642000_13.10.e011279.117","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0962"},{"key":"2026041300250642000_13.10.e011279.118","doi-asserted-by":"publisher","DOI":"10.1002\/path.2929"},{"key":"2026041300250642000_13.10.e011279.119","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/301527a0","article-title":"A severe combined immunodeficiency mutation in the mouse","volume":"301","author":"Bosma","year":"1983","journal-title":"Nature New Biol"},{"key":"2026041300250642000_13.10.e011279.120","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(95)90360-7"},{"key":"2026041300250642000_13.10.e011279.121","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90760-5"},{"key":"2026041300250642000_13.10.e011279.122","doi-asserted-by":"publisher","DOI":"10.1126\/science.2360047"},{"key":"2026041300250642000_13.10.e011279.123","doi-asserted-by":"publisher","DOI":"10.2337\/diab.32.3.247"},{"key":"2026041300250642000_13.10.e011279.124","doi-asserted-by":"publisher","DOI":"10.2337\/diab.42.11.1574"},{"key":"2026041300250642000_13.10.e011279.125","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.20.9625"},{"key":"2026041300250642000_13.10.e011279.126","doi-asserted-by":"publisher","DOI":"10.2337\/diab.47.8.1212"},{"key":"2026041300250642000_13.10.e011279.127","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.8.2481"},{"key":"2026041300250642000_13.10.e011279.128","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2001-12-0207"},{"key":"2026041300250642000_13.10.e011279.129","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(02)00505-8"},{"key":"2026041300250642000_13.10.e011279.130","doi-asserted-by":"publisher","DOI":"10.1038\/ni1527"},{"key":"2026041300250642000_13.10.e011279.131","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.2.377"},{"key":"2026041300250642000_13.10.e011279.132","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.3.956.bloodjournal873956"},{"key":"2026041300250642000_13.10.e011279.133","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00721-2"},{"key":"2026041300250642000_13.10.e011279.134","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201800636R"},{"key":"2026041300250642000_13.10.e011279.135","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.4049\/jimmunol.177.7.4521","article-title":"Homeostatic Proliferation as an Isolated Variable Reverses CD8+ T Cell Anergy and Promotes Tumor Rejection","volume":"177","author":"Brown","year":"2006","journal-title":"The Journal of Immunology"},{"key":"2026041300250642000_13.10.e011279.136","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.4.557"},{"key":"2026041300250642000_13.10.e011279.137","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.4.549"},{"key":"2026041300250642000_13.10.e011279.138","doi-asserted-by":"crossref","unstructured":"Pearson T , Greiner DL , Shultz LD . Creation of \u201cHumanized\u201d Mice to Study Human Immunity. CP in Immunology 2008;81. doi:10.1002\/0471142735.im1521s81","DOI":"10.1002\/0471142735.im1521s81"},{"key":"2026041300250642000_13.10.e011279.139","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001203R"},{"key":"2026041300250642000_13.10.e011279.140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173754","article-title":"Creation of an immunodeficient HLA-transgenic mouse (HUMAMICE) and functional validation of human immunity after transfer of HLA-matched human cells","volume":"12","author":"Zeng","year":"2017","journal-title":"PLoS ONE"},{"key":"2026041300250642000_13.10.e011279.141","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2017.106"},{"key":"2026041300250642000_13.10.e011279.142","doi-asserted-by":"publisher","DOI":"10.1038\/nri2000"},{"key":"2026041300250642000_13.10.e011279.143","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008516","article-title":"MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers","volume":"12","author":"Eguren-Santamaria","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.144","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-38946-z","article-title":"Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors","volume":"14","author":"Schmidt","year":"2023","journal-title":"Nat Commun"},{"key":"2026041300250642000_13.10.e011279.145","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/19420862.2018.1518948","article-title":"Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1\/PD-1 targeted immunotherapy","volume":"10","author":"Lin","year":"2018","journal-title":"MAbs"},{"key":"2026041300250642000_13.10.e011279.146","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ygyno.2019.10.011","article-title":"An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer","volume":"156","author":"Gitto","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026041300250642000_13.10.e011279.147","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00786-z","article-title":"Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model","volume":"8","author":"Jespersen","year":"2017","journal-title":"Nat Commun"},{"key":"2026041300250642000_13.10.e011279.148","doi-asserted-by":"publisher","DOI":"10.1007\/BF02994007"},{"key":"2026041300250642000_13.10.e011279.149","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood.V89.11.3919","article-title":"Primitive Human Hematopoietic Cells Are Enriched in Cord Blood Compared With Adult Bone Marrow or Mobilized Peripheral Blood as Measured by the Quantitative In Vivo SCID-Repopulating Cell Assay","volume":"89","author":"Wang","year":"1997","journal-title":"Blood"},{"key":"2026041300250642000_13.10.e011279.150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006921","article-title":"Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment","volume":"11","author":"Chiorazzi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.151","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-20-0686"},{"key":"2026041300250642000_13.10.e011279.152","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.10.6477"},{"key":"2026041300250642000_13.10.e011279.153","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0516"},{"key":"2026041300250642000_13.10.e011279.154","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2755"},{"key":"2026041300250642000_13.10.e011279.155","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.169.1.204"},{"key":"2026041300250642000_13.10.e011279.156","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-157016"},{"key":"2026041300250642000_13.10.e011279.157","doi-asserted-by":"crossref","first-page":"6145","DOI":"10.4049\/jimmunol.1103660","article-title":"Development of Mature and Functional Human Myeloid Subsets in Hematopoietic Stem Cell-Engrafted NOD\/SCID\/IL2r\u03b3KO Mice","volume":"188","author":"Tanaka","year":"2012","journal-title":"The Journal of Immunology"},{"key":"2026041300250642000_13.10.e011279.158","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.009"},{"key":"2026041300250642000_13.10.e011279.159","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-022-00546-2"},{"key":"2026041300250642000_13.10.e011279.160","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2858"},{"key":"2026041300250642000_13.10.e011279.161","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/iid3.124","article-title":"Improved B cell development in humanized NOD-scid IL2R\u03b3null mice transgenically expressing human stem cell factor, granulocyte-macrophage colony-stimulating factor and interleukin-3","volume":"4","author":"Jangalwe","year":"2016","journal-title":"Immun Inflamm Dis"},{"key":"2026041300250642000_13.10.e011279.162","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0209034","article-title":"Improved multilineage human hematopoietic reconstitution and function in NSGS mice","volume":"13","author":"Wunderlich","year":"2018","journal-title":"PLoS ONE"},{"key":"2026041300250642000_13.10.e011279.163","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018023887"},{"key":"2026041300250642000_13.10.e011279.164","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88181","article-title":"A xenograft model of macrophage activation syndrome amenable to anti-CD33 and anti-IL-6R treatment","volume":"1","author":"Wunderlich","year":"2016","journal-title":"JCI Insight"},{"key":"2026041300250642000_13.10.e011279.165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00186","article-title":"Posttransplant Hemophagocytic Lymphohistiocytosis Driven by Myeloid Cytokines and Vicious Cycles of T-Cell and Macrophage Activation in Humanized Mice","volume":"10","author":"Yoshihara","year":"2019","journal-title":"Front Immunol"},{"key":"2026041300250642000_13.10.e011279.166","doi-asserted-by":"crossref","unstructured":"Herndler-Brandstetter D , Shan L , Yao Y , et al . Humanized mouse model supports development, function, and tissue residency of human natural killer cells. Proc Natl Acad Sci USA 2017;114. doi:10.1073\/pnas.1705301114","DOI":"10.1073\/pnas.1705301114"},{"key":"2026041300250642000_13.10.e011279.167","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202200045R","article-title":"Enhanced development of functional human NK cells in NOD-scid-IL2rgnull mice expressing human IL15","volume":"36","author":"Aryee","year":"2022","journal-title":"FASEB J"},{"key":"2026041300250642000_13.10.e011279.168","doi-asserted-by":"crossref","unstructured":"Zheng Y , Sefik E , Astle J , et al . Human neutrophil development and functionality are enabled in a humanized mouse model. Proc Natl Acad Sci USA 2022;119. doi:10.1073\/pnas.2121077119","DOI":"10.1073\/pnas.2121077119"},{"key":"2026041300250642000_13.10.e011279.169","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-07478-2","article-title":"Selective expansion of myeloid and NK cells in humanized mice yields human-like vaccine responses","volume":"9","author":"Douam","year":"2018","journal-title":"Nat Commun"},{"key":"2026041300250642000_13.10.e011279.170","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001963","article-title":"Human CD141+ dendritic cells (cDC1) are impaired in patients with advanced melanoma but can be targeted to enhance anti-PD-1 in a humanized mouse model","volume":"9","author":"Lee","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.171","doi-asserted-by":"publisher","DOI":"10.1084\/jem.175.4.1033"},{"key":"2026041300250642000_13.10.e011279.172","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4388"},{"key":"2026041300250642000_13.10.e011279.173","doi-asserted-by":"publisher","DOI":"10.1038\/nm1431"},{"key":"2026041300250642000_13.10.e011279.174","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1115050108"},{"key":"2026041300250642000_13.10.e011279.175","doi-asserted-by":"crossref","unstructured":"Li Y , Teteloshvili N , Tan S , et al . Humanized Mice Reveal New Insights Into the Thymic Selection of Human Autoreactive CD8+ T Cells. Front Immunol 2019;10. doi:10.3389\/fimmu.2019.00063","DOI":"10.3389\/fimmu.2019.00063"},{"key":"2026041300250642000_13.10.e011279.176","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2020.100061","article-title":"Negative selection of human T cells recognizing a naturally-expressed tissue-restricted antigen in the human thymus","volume":"3","author":"Madley","year":"2020","journal-title":"J Transl Autoimmun"},{"key":"2026041300250642000_13.10.e011279.177","doi-asserted-by":"crossref","unstructured":"Kalscheuer H , Danzl N , Onoe T , et al . A Model for Personalized in Vivo Analysis of Human Immune Responsiveness. Sci Transl Med 2012;4. doi:10.1126\/scitranslmed.3003481","DOI":"10.1126\/scitranslmed.3003481"},{"key":"2026041300250642000_13.10.e011279.178","doi-asserted-by":"crossref","unstructured":"Dudek TE , No DC , Seung E , et al . Rapid evolution of HIV-1 to functional CD8+ T-cell rResponses in humanized BLT mice. Retrovirology (Auckl) 2012;9. doi:10.1186\/1742-4690-9-S2-P249","DOI":"10.1186\/1742-4690-9-S2-P249"},{"key":"2026041300250642000_13.10.e011279.179","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1016\/j.celrep.2017.08.003","article-title":"Alloimmune Responses of Humanized Mice to Human Pluripotent Stem Cell Therapeutics","volume":"20","author":"Kooreman","year":"2017","journal-title":"Cell Rep"},{"key":"2026041300250642000_13.10.e011279.180","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12180"},{"key":"2026041300250642000_13.10.e011279.181","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bbmt.2013.06.007","article-title":"Mice engrafted with human fetal thymic tissue and hematopoietic stem cells develop pathology resembling chronic graft-versus-host disease","volume":"19","author":"Lockridge","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026041300250642000_13.10.e011279.182","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001513","article-title":"Preclinical platform for long-term evaluation of immuno-oncology drugs using hCD34+ humanized mouse model","volume":"8","author":"Park","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.183","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20081720"},{"key":"2026041300250642000_13.10.e011279.184","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1000475107"},{"key":"2026041300250642000_13.10.e011279.185","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.8"},{"key":"2026041300250642000_13.10.e011279.186","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019826","article-title":"Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells","volume":"6","author":"Danner","year":"2011","journal-title":"PLoS ONE"},{"key":"2026041300250642000_13.10.e011279.187","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097860","article-title":"Immune humanization of immunodeficient mice using diagnostic bone marrow aspirates from carcinoma patients","volume":"9","author":"Werner-Klein","year":"2014","journal-title":"PLoS One"},{"key":"2026041300250642000_13.10.e011279.188","doi-asserted-by":"crossref","DOI":"10.1038\/srep28093","article-title":"Differential effect of HLA class-I versus class-II transgenes on human T and B cell reconstitution and function in NRG mice","volume":"6","author":"Majji","year":"2016","journal-title":"Sci Rep"},{"key":"2026041300250642000_13.10.e011279.189","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.4049\/jimmunol.1201518","article-title":"Characterization of Human Antiviral Adaptive Immune Responses during Hepatotropic Virus Infection in HLA-Transgenic Human Immune System Mice","volume":"191","author":"Billerbeck","year":"2013","journal-title":"The Journal of Immunology"},{"key":"2026041300250642000_13.10.e011279.190","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/eji.201848001","article-title":"Accelerated thymopoiesis and improved T\u2010cell responses in HLA\u2010A2\/\u2010DR2 transgenic BRGS\u2010based human immune system mice","volume":"49","author":"Masse\u2010Ranson","year":"2019","journal-title":"Eur J Immunol"},{"key":"2026041300250642000_13.10.e011279.191","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"2026041300250642000_13.10.e011279.192","doi-asserted-by":"publisher","DOI":"10.1126\/science.1093933"},{"key":"2026041300250642000_13.10.e011279.193","doi-asserted-by":"publisher","DOI":"10.1038\/76923"},{"key":"2026041300250642000_13.10.e011279.194","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901647"},{"key":"2026041300250642000_13.10.e011279.195","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-018-0071-6"},{"key":"2026041300250642000_13.10.e011279.196","doi-asserted-by":"crossref","unstructured":"Takahashi T , Katano I , Ito R , et al . Enhanced Antibody Responses in a Novel NOG Transgenic Mouse with Restored Lymph Node Organogenesis. Front Immunol 2018;8. doi:10.3389\/fimmu.2017.02017","DOI":"10.3389\/fimmu.2017.02017"},{"key":"2026041300250642000_13.10.e011279.197","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01914-8","article-title":"Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis","volume":"23","author":"Gammelgaard","year":"2024","journal-title":"Mol Cancer"},{"key":"2026041300250642000_13.10.e011279.198","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0273076","article-title":"Critical evaluation of an autologous peripheral blood mononuclear cell-based humanized cancer model","volume":"17","author":"Janakiraman","year":"2022","journal-title":"PLoS ONE"},{"key":"2026041300250642000_13.10.e011279.199","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.4049\/jimmunol.1900807","article-title":"The Tumor-Immune Response Is Not Compromised by Mesenchymal Stromal Cells in Humanized Mice","volume":"203","author":"Moquin-Beaudry","year":"2019","journal-title":"The Journal of Immunology"},{"key":"2026041300250642000_13.10.e011279.200","doi-asserted-by":"crossref","first-page":"100153","DOI":"10.1016\/j.crmeth.2021.100153","article-title":"Autologous humanized mouse models of iPSC-derived tumors enable characterization and modulation of cancer-immune cell interactions","volume":"2","author":"Moquin-Beaudry","year":"2022","journal-title":"Cell Reports Methods"},{"key":"2026041300250642000_13.10.e011279.201","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1158\/1538-7445.AM2015-261","article-title":"Abstract 261: Nivolumab and urelumab enhance antitumor activity of human T lymphocytes engrafted in Rag2-\/-IL2R\u03b3null immunodeficient mice","volume":"75","author":"Sanmamed","year":"2015","journal-title":"Cancer Res"},{"key":"2026041300250642000_13.10.e011279.202","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008066","article-title":"Autologous human preclinical modeling of melanoma interpatient clinical responses to immunotherapeutics","volume":"12","author":"Phoon","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.203","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.03.001"},{"key":"2026041300250642000_13.10.e011279.204","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1"},{"key":"2026041300250642000_13.10.e011279.205","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41586-022-04439-0","article-title":"A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells","volume":"603","author":"Seung","year":"2022","journal-title":"Nature New Biol"},{"key":"2026041300250642000_13.10.e011279.206","doi-asserted-by":"crossref","first-page":"108879","DOI":"10.1016\/j.isci.2024.108879","article-title":"Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model","volume":"27","author":"Wang","year":"2024","journal-title":"iScience"},{"key":"2026041300250642000_13.10.e011279.207","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat Cancer"},{"key":"2026041300250642000_13.10.e011279.208","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3725"},{"key":"2026041300250642000_13.10.e011279.209","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2845"},{"key":"2026041300250642000_13.10.e011279.210","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-3123"},{"key":"2026041300250642000_13.10.e011279.211","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood.2023023381","article-title":"CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy","volume":"143","author":"Sam","year":"2024","journal-title":"Blood"},{"key":"2026041300250642000_13.10.e011279.212","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci Transl Med"},{"key":"2026041300250642000_13.10.e011279.213","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","article-title":"Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.214","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0874"},{"key":"2026041300250642000_13.10.e011279.215","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000416","article-title":"Characterization of human cancer xenografts in humanized mice","volume":"8","author":"Rios-Doria","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.216","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005642","article-title":"PD-1\/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model","volume":"12","author":"Ma","year":"2016","journal-title":"PLoS Pathog"},{"key":"2026041300250642000_13.10.e011279.217","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0518-z","article-title":"Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts","volume":"7","author":"Capasso","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2026041300250642000_13.10.e011279.218","doi-asserted-by":"crossref","unstructured":"Lee YS , Kim TS , Kim DK . T lymphocytes derived from human cord blood provide effective antitumor immunotherapy against a human tumor. BMC Cancer 2011;11. doi:10.1186\/1471-2407-11-225","DOI":"10.1186\/1471-2407-11-225"},{"key":"2026041300250642000_13.10.e011279.219","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"2026041300250642000_13.10.e011279.220","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies","volume":"29","author":"Leclercq-Cohen","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026041300250642000_13.10.e011279.221","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011"},{"key":"2026041300250642000_13.10.e011279.222","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1294814","article-title":"Preclinical evaluation of the efficacy of an antibody to human SIRP\u03b1 for cancer immunotherapy in humanized mouse models","volume":"14","author":"Saito","year":"2023","journal-title":"Front Immunol"},{"key":"2026041300250642000_13.10.e011279.223","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4049\/jimmunol.2101109","article-title":"An In Vivo Model of Human Macrophages in Metastatic Melanoma","volume":"209","author":"Voillet","year":"2022","journal-title":"The Journal of Immunology"},{"key":"2026041300250642000_13.10.e011279.224","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20182163","article-title":"Human KIT+ myeloid cells facilitate visceral metastasis by melanoma","volume":"218","author":"Yu","year":"2021","journal-title":"J Exp Med"},{"key":"2026041300250642000_13.10.e011279.225","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-1815"},{"key":"2026041300250642000_13.10.e011279.226","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj9779","article-title":"Addition of interleukin-2 overcomes resistance to neoadjuvant CTLA4 and PD1 blockade in ex vivo patient tumors","volume":"14","author":"Kaptein","year":"2022","journal-title":"Sci Transl Med"},{"key":"2026041300250642000_13.10.e011279.227","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1158\/2159-8290.CD-23-1263","article-title":"CD8-Targeted IL2 Unleashes Tumor-Specific Immunity in Human Cancer Tissue by Reviving the Dysfunctional T-cell Pool","volume":"14","author":"Kaptein","year":"2024","journal-title":"Cancer Discov"},{"key":"2026041300250642000_13.10.e011279.228","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.11.014"},{"key":"2026041300250642000_13.10.e011279.229","doi-asserted-by":"crossref","DOI":"10.1038\/s44276-023-00035-5","article-title":"Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancer","volume":"2","author":"Sobhani","year":"2024","journal-title":"BJC Rep"},{"key":"2026041300250642000_13.10.e011279.230","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7"},{"key":"2026041300250642000_13.10.e011279.231","doi-asserted-by":"crossref","first-page":"100039","DOI":"10.1016\/j.aichem.2023.100039","article-title":"Advances in Artificial Intelligence (AI)-assisted approaches in drug screening","volume":"2","author":"Singh","year":"2024","journal-title":"Artificial Intelligence Chemistry"},{"key":"2026041300250642000_13.10.e011279.232","doi-asserted-by":"crossref","DOI":"10.1016\/j.crmeth.2023.100413","article-title":"Machine learning approaches to predict drug efficacy and toxicity in oncology","volume":"3","author":"Badwan","year":"2023","journal-title":"Cell Rep Methods"},{"key":"2026041300250642000_13.10.e011279.233","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1670019","article-title":"Organotypic tumor slice cultures provide a versatile platform for immuno-oncology and drug discovery","volume":"8","author":"Sivakumar","year":"2019","journal-title":"Oncoimmunology"},{"key":"2026041300250642000_13.10.e011279.234","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1008764","article-title":"LY6G6D is a selectively expressed colorectal cancer antigen that can be used for targeting a therapeutic T-cell response by a T-cell engager","volume":"13","author":"Corrales","year":"2022","journal-title":"Front Immunol"},{"key":"2026041300250642000_13.10.e011279.235","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-0472"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T07:25:42Z","timestamp":1776065142000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":235,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,29]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/jitc-2024-011279"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011279","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}